P/E ratio for Anavex Life Sciences (AVXL)
P/E ratio as of August 2022 (TTM): -21.6
According to Anavex Life Sciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -21.5741. At the end of 2021 the company had a P/E ratio of -33.0.
P/E ratio history for Anavex Life Sciences from 2007 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -33.0 | 217.31% |
| 2020 | -10.4 | 82.34% |
| 2019 | -5.70 | -13.78% |
| 2018 | -6.62 | -47.27% |
| 2017 | -12.5 | 40.51% |
| 2016 | -8.93 | 9.5% |
| 2015 | -8.15 | 1178.17% |
| 2014 | -0.6379 | -88.22% |
| 2013 | -5.42 | 84.8% |
| 2012 | -2.93 | -43.33% |
| 2011 | -5.17 | -46.31% |
| 2010 | -9.63 | 2.01% |
| 2009 | -9.44 | 13.33% |
| 2008 | -8.33 | -82.13% |
| 2007 | -46.6 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.